Adhera Therapeutics, Inc. (ATRX)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jun 2, 2026, 9:30 AM EST
Adhera Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
1.16K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 252.00K | 176.00K | 231.58% |
| Dec 31, 2018 | 76.00K | - | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Alzex Neuropharma | 4.73M |
| DNAPrint Genomics | 1.93M |
| Trevena | 546.00K |
| RegeneRx Biopharmaceuticals | 76.76K |
| Proteonomix | 26.00K |
Adhera Therapeutics News
- 3 years ago - Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes - GlobeNewsWire
- 4 years ago - Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist - GlobeNewsWire
- 4 years ago - Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin - GlobeNewsWire
- 4 years ago - Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ - GlobeNewsWire
- 4 years ago - Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board - GlobeNewsWire
- 4 years ago - Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace - GlobeNewsWire
- 4 years ago - Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders - GlobeNewsWire
- 4 years ago - Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors - GlobeNewsWire